Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1210 plus apatinib in PD-L1-positive and/or dMMR relapsed or refractory gynecologic carcinoma
ChiCTR2000029752Phase 2Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Feb 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of camrelizumab and Rivoceranib in gynecologic carcinoma, endometrial cancer (EC), Cervical Cancer (CC) and 1 more, sponsored by Ruijin Hospital. Primary endpoint: Objective tumor response rate. Started Feb 2020; status: recruiting.
02
Drugs
camrelizumabRivoceranib
03
Conditions
gynecologic carcinomaendometrial cancer (EC)Cervical Cancer (CC)ovarian cancer
Beyond the preview
Go deeper on ChiCTR2000029752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000029752.